Vincerx Pharma (Vincerx Pharma) Cash-to-Debt : 2.30 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vincerx Pharma's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.30.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vincerx Pharma could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Vincerx Pharma's Cash-to-Debt or its related term are showing as below:

VINC' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.3 Med: 16.91 Max: No Debt
Current: 2.3

During the past 5 years, Vincerx Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 2.30. And the median was 16.91.

VINC's Cash-to-Debt is ranked worse than
65.61% of 1486 companies
in the Biotechnology industry
Industry Median: 6.9 vs VINC: 2.30

Vincerx Pharma Cash-to-Debt Historical Data

The historical data trend for Vincerx Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vincerx Pharma Cash-to-Debt Chart

Vincerx Pharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

No Debt

26.70

15.27

5.11

Vincerx Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial												12.13	9.05	7.52	5.11	2.30

Competitive Comparison of Vincerx Pharma's Cash-to-Debt

For the Biotechnology subindustry, Vincerx Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vincerx Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's Cash-to-Debt falls into.

Vincerx Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vincerx Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12.782	/	(1.162	+	1.34)
	=	5.11

Vincerx Pharma's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.11	/	(1.198	+	1.021)
	=	2.30

Vincerx Pharma (NAS:VINC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vincerx Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vincerx Pharma (Vincerx Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306

Website

https://www.vincerx.com

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.

Executives

Alexander A. Seelenberger	officer: Chief Financial Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi	director, 10 percent owner, officer: Chief Operations Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy	director, 10 percent owner, officer: President and CEO	995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas	officer: See Remarks	180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe	director	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang	officer: Chief Business Officer	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang	officer: Chief Technology Officer	260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens	director	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus	officer: Chief Medical Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd	10 percent owner	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054